Page 41 - CIBERSAM2016-ENG

Most relevant scientific articles
• Artigas F., Schenker E., Celada P., Spedding M. Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. Nature Reviews Drug Discovery. 2016;16(1):1-2.
• Ferres-Coy A., Galofre M., Pilar-Cuellar F., Vidal R., Paz V., Ruiz-Bronchal E. et al. Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration. Molecular Psychiatry. 2016;21(3):328-338.
• Santana N, Artigas F. Expression of Serotonin2C Receptors in Pyramidal and GABAergic Neurons of Rat Prefrontal Cortex: A Comparison with Striatum.Cerebral cortex (New York, N.Y.: 1991). 2016;.
• Jimenez-Sanchez L., Linge R., Campa L., Valdizan E.M., Pazos A., Diaz A. et al. Behavioral, neurochemical and molecular changes after acute deep brain stimulation of the infralimbic prefrontal cortex. Neuropharmacology. 2016; 108:91-102.
• Riga M.S., Sanchez C., Celada P., Artigas F.. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology. 2016; 108:73-81.
Hightlights
The group has led a total of 10 grants during 2016, including 5 Spanish competitive grants (SAF2015- 68346-P, SAF2016-75797-R, PI12/00156, PI13/01390 y RTC-2014-2812), 1 Catalan grant (2014SGR798), 3 contracts with pharmaceutical companies (H. Lundbeck A/S; nLife Therapeutics) and 1 grant from the Alicia Koplowitz Foundation.
From the studies carried out during 2016, we highlight a) the development of novel strategies using RNAi for the, study of the pathophysiology and treatment of neuropsychiatric conditions, including major depressive disorder and Parkinson’s disease, b) the study of the mechanism of action of fast acting antidepressant strategies, including glutamatergic agents such as ketamine, c) study of the mechanism
of action of novel antidepressant drugs, such as vortioxetine, d) development of preclinical models of schizophrenia, and e) identification of the infralimbic prefrontal cortex as a key area in the pathophysiology and treatment of major depression.
The group keeps having a solid international reputation in Neuropsychopharmacology as indicated by the large number of citations (the PI of G02 has an h index of 60, one of the highest in Spanish Neuroscience). Currently, 3 articles published over the last 5 years are considered as “Highly Cited Papers” by the Web of Science, one of them also being a “Popular paper”.
Among the papers published during 2016, we highlight i) an original article published in Molecular Psychiatry on the use of novel antidepressant RNAi strategies, in collaboration with groups G12 and G20 from CIBERSAM., ii) a paper in Nat Commun on the role of the 5-HT system in anxiety epigenetics, in collaboration with a group from Cornell Univ (NY, USA), and iii) a commentary in Nat Rev Drug Discov, in collaboration with the former members of the IMI-NEWMEDS EU project.
SAM
research groups 41